GLP-1 Weight Loss by Week: What to Expect on Semaglutide and Tirzepatide
Why the week-by-week question is complicated
Patients starting GLP-1 therapy usually ask: "How much should I have lost by week 4?" or "When does it really start working?" The honest answer is that the timeline varies substantially:
- Starter doses (0.25 mg semaglutide, 2.5 mg tirzepatide) are sub-therapeutic — very little weight loss is expected
- Full therapeutic doses take 4–20 weeks to reach (depending on escalation speed)
- Individual response varies widely — some patients lose 5% in 8 weeks; others lose 2% in the same period
- Early weight loss is partly water weight and transit time, not purely fat
The data below is population-level averages from Phase 3 trials. Individual experience will vary around these averages.
Semaglutide (Wegovy) weight loss timeline
From STEP 1 (68-week trial, semaglutide 2.4 mg vs placebo, n=1,961 obese adults):
| Timepoint | Average weight loss (semaglutide) | Average weight loss (placebo) |
|---|---|---|
| Week 4 | ~1.3% | ~0.3% |
| Week 8 | ~2.8% | ~0.7% |
| Week 12 | ~4.5% | ~1.3% |
| Week 20 | ~7.2% | ~2.1% |
| Week 28 | ~9.8% | ~2.6% |
| Week 40 | ~12.4% | ~2.8% |
| Week 52 | ~14.1% | ~2.5% |
| Week 68 | ~15.0% | ~2.5% |
Approximate values reconstructed from published figures.
Key observation: Most weight loss occurs in the first 36 weeks. After week 36–40, the rate of loss slows as patients approach their new defended weight. By week 68, most patients have reached or are near their weight loss plateau.
Tirzepatide (Zepbound) weight loss timeline
From SURMOUNT-1 (72-week trial, tirzepatide 5/10/15 mg vs placebo, n=2,539 obese adults):
| Timepoint | Tirzepatide 15 mg | Tirzepatide 10 mg | Tirzepatide 5 mg | Placebo |
|---|---|---|---|---|
| Week 12 | ~6% | ~5% | ~4% | ~1% |
| Week 24 | ~12% | ~10% | ~8% | ~2% |
| Week 36 | ~17% | ~14% | ~11% | ~2% |
| Week 52 | ~19% | ~17% | ~13% | ~2% |
| Week 72 | ~20.9% | ~19.5% | ~15.0% | ~3.1% |
Approximate values from published figures.
Key observation: Tirzepatide produces faster early weight loss than semaglutide in these respective trial data sets — though direct cross-trial comparisons have significant limitations. The SURMOUNT-5 head-to-head trial provides the best direct comparison.
The dose escalation effect: why early weeks are slow
The slow start is not a drug failure — it is the dose escalation working as designed.
During weeks 1–4 (semaglutide 0.25 mg; tirzepatide 2.5 mg), the dose is sub-therapeutic. It exists to reduce side effects, not produce weight loss. Expecting significant weight loss at the starter dose is a calibration error many patients make.
The therapeutic dose is:
- Semaglutide: 1 mg and above (weeks 9+)
- Tirzepatide: 5 mg and above (weeks 5+)
Before these thresholds are reached, weight loss should be measured in tenths of a percentage point per week, not pounds per week.
What "typical" looks like in practice
Clinical trial averages smooth out high individual variance. In practice:
High responders (approximately 20–25% of patients)
- Lose weight faster than average — often 5–8% by week 12, 15%+ by week 24
- Often experience strong early appetite suppression even at lower doses
- May reach their plateau weight faster
Average responders (approximately 50–60% of patients)
- Track reasonably close to the trial averages
- Feel appetite suppression at escalating doses but not dramatically at starter dose
- Reach plateau weight around weeks 36–52
Low responders (approximately 15–25% of patients)
- Lose significantly less than average at any given timepoint
- May not reach the 5% loss threshold needed for insurance continuation criteria
- May be candidates for dose escalation to maximum or for switching drug
The first 4 weeks: what most patients actually notice
Trial data on week-by-week experience from patient reporting (not just weight on scale):
Week 1: Usually minimal changes. Some patients notice slight decrease in appetite or food noise. A small number experience nausea 24–48 hours post-injection.
Week 2: Appetite suppression becomes noticeable for most patients at 0.25 mg. Eating somewhat less without trying. Still eating most foods normally.
Week 3–4: Many patients report this is the first week where food noise significantly decreases. "I forgot to eat lunch" type reports. Scale movement is small (1–3 lbs typical) but the psychological experience of changed appetite is often significant.
After first dose escalation (week 5): Nausea often peaks here. Appetite suppression intensifies. The combination can lead to under-eating if not deliberate about protein intake.
Weight loss plateaus: when and why
Most patients hit a plateau — a period of no further weight loss — around weeks 36–52. This is not drug failure. It is the body reaching a new energy balance where appetite suppression matches the metabolic adaptation.
What causes the plateau:
- Reduced resting metabolic rate (adaptive thermogenesis) — the body burns fewer calories at the new lower weight
- Reduced physical activity-related calorie burn (less body mass to move)
- Partial appetite recovery as tolerance to the drug's central effects develops
What to do at a plateau:
- Dose escalation to the next tier (if not already at maximum)
- Increase resistance training (increases muscle mass and metabolic rate)
- Track protein specifically — lean mass loss at a plateau means the composition is changing even if the scale isn't
- Allow time — some plateaus resolve after 4–8 weeks without any change
Non-scale victories: what else changes
Weight loss is not the only marker of progress. Many patients report meaningful changes at timepoints where scale movement is modest:
- Blood pressure normalising
- HbA1c improving (in T2D patients)
- Sleep apnoea symptoms reducing
- Joint pain reducing
- Energy levels improving
- Clothing fitting differently before the scale changes meaningfully
Tracking these alongside weight provides a more complete picture of therapeutic progress.
Summary
GLP-1 weight loss follows a predictable pattern: slow start during dose escalation (weeks 1–16), accelerating loss during maintenance dosing (weeks 16–40), followed by a plateau around weeks 36–52. Semaglutide averages approximately 15% weight loss at 68 weeks; tirzepatide averages approximately 21% at 72 weeks. Individual response varies substantially — approximately 20% of patients are high responders and 20% are low responders. Early weeks measure psychological change (appetite, food noise) more than scale movement; the scale changes most rapidly between weeks 8 and 36.